Literature DB >> 11205881

Chronic pharmacological treatment with certain antidepressants alters the expression and DNA-binding activity of transcription factor AP-2.

M Damberg1, J Ekblom, L Oreland.   

Abstract

Several of the genes in the serotonergic and the dopaminergic systems have consensus binding sites for the AP-2 transcription factor family in their regulatory regions. Imbalances in these systems have been implicated in many psychiatric disorders, including depression and bipolar affective disorder. We have made an effort to further elucidate the molecular mechanisms of drugs used for affective disorders. Recently, we analyzed the effects of chronic treatment with certain antidepressants on AP-2 in rat brain. The present study demonstrates that chronic administration of three different classes of antidepressants modulates the DNA-binding activity of AP-2 in the rat brain. Chronic administration of citalopram (10 mg/kg), imipramin (10 mg/kg) and lithium-chloride (40 mg/kg) significantly decreased DNA-binding activity of AP-2. Furthermore, citalopram (10 mg/kg) and imipramin (10 mg/kg) significantly decreased the amount of AP-2alpha protein as determined by ELISA. In addition, citalopram (10 mg/kg) significantly decreased the amount of AP-2beta protein. In contrast, chronic administration of lithium-chloride (40 mg/kg) did not affect the amount of the two AP-2 isoforms. An increased understanding of the function of transcription factors and their involvement in human disease, such as depression, could make it possible in the future to selectively modulate relevant target genes directly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205881     DOI: 10.1016/s0024-3205(00)00969-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease.

Authors:  Jessie Theuns; Nathalie Brouwers; Sebastiaan Engelborghs; Kristel Sleegers; Veerle Bogaerts; Ellen Corsmit; Tim De Pooter; Cornelia M van Duijn; Peter P De Deyn; Christine Van Broeckhoven
Journal:  Am J Hum Genet       Date:  2006-04-10       Impact factor: 11.025

Review 2.  Transcription factor AP-2 and monoaminergic functions in the central nervous system.

Authors:  M Damberg
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

3.  Involvement of AP-2 binding sites in regulation of human beta-glucuronidase.

Authors:  Christiane Kunert-Keil; Bernhard Sperker; Sandra Bien; Gabriele Wolf; Markus Grube; Heyo K Kroemer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-28       Impact factor: 3.000

Review 4.  Bipolar disorder and mechanisms of action of mood stabilizers.

Authors:  Stanley I Rapoport; Mireille Basselin; Hyung-Wook Kim; Jagadeesh S Rao
Journal:  Brain Res Rev       Date:  2009-06-23

5.  H3K4 tri-methylation in synapsin genes leads to different expression patterns in bipolar disorder and major depression.

Authors:  Cristiana Cruceanu; Martin Alda; Corina Nagy; Erika Freemantle; Guy A Rouleau; Gustavo Turecki
Journal:  Int J Neuropsychopharmacol       Date:  2012-05-09       Impact factor: 5.176

6.  Brainstem levels of transcription factor AP-2 in rat are changed after treatment with phenelzine, but not with citalopram.

Authors:  Cecilia Berggard; Mattias Damberg; Lars Oreland
Journal:  BMC Pharmacol       Date:  2005-01-21

7.  Phenelzine treatment increases transcription factor AP-2 levels in rat brain.

Authors:  Mattias Damberg; Cecilia Berggård; Lars Oreland
Journal:  BMC Pharmacol       Date:  2003-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.